Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information



335 Bryant Street
3rd Floor
Palo Alto, CA, 94301
London, GBR
Berkeley Square House
Berkeley Square
London, W1J 6BR, GBR
Shanghai, CHN
Suite 522, Shanghai Centre
1376 Nanjing Road West
Shanghai, 200040, CHN


Adjunct Partner
Adjunct Partner
Adjunct Partner
Operating Partner
Adjunct Venture Partner
Show All People


Essex Woodlands Health Ventures

Essex Woodlands was founded in 1985 with the establishment of Essex Venture Fund I, LP. Since 1985, the Partnership has raised seven additional funds with nearly $2.5 billion under management, making Essex Woodlands one of the world’s largest and most established healthcare venture capital firms. The team is comprised of 23 professionals with principal offices in Palo Alto, Houston, New York and London. This team brings over 300 years of collective healthcare experience.

For over 20 years, the firm has maintained its dedicated focus to diversified healthcare investing—primarily serving as lead investor in the founding or the critical financings of over 100 healthcare companies in pharmaceutical, biotechnology, medical device, services and information technology sectors. In addition to its long-standing commitment to early stage companies, the firm has over a decade of experience as a leading late-stage healthcare investor, which includes mature venture, growth equity and PIPE investment opportunities.

Recent Milestones


Company Date Round Size Participants
Qspex Technologies 1/2014Series E$15M2
PreCision Dermatology 9/2013Debt$67M7
Revance Therapeutics 4/2013Series E$33M3
Catalyst Biosciences 4/2013Venture Round$5.07M6
Kona Medical 12/2012Series C$10M5
Catalyst Biosciences 9/2012Partial Close$13.4M5
Qspex Technologies 6/2012Series D$20.5M2
Kona Medical 5/2012Series C$30M4
NeoVista 5/2012Partial Close$6M5
IntegenX 12/2011Series C$40M7
BreatheAmerica 9/2011Series B$22M1
Entellus Medical 8/2011Series E$35M5
Revance Therapeutics 6/2011Series D$45M7
Symphogen 2/2011Series F$135M2
Symphogen 1/2011Private Equity€100M3
Endologix 10/2010Venture Round$15M1
CellBiosciences 10/2010Series F$20M8
Accumetrics 9/2010Venture Round$7M5
Complete Genomics 8/2010Series E$39M7
TearScience 5/2010Series C$44.5M6
Accumetrics 1/2010Series E$16.6M5
ikaSystems 1/2010Private Equity$120M1
Molecular Partners 12/2009Series B$44.2M5
Entellus Medical 11/2009Series D$30M3
Xanodyne 10/2009Series D$87.8M7
Complete Genomics 8/2009Series D$45M6
Oraya Therapeutics 7/2009Series C$42M4
Chroma Therapeutics 6/2009Venture Round$24.5M6
Symphogen 2/2009Private Equity€33M1
Catalyst Biosciences 12/2008Series C$40M7
Nellix 3/2008Series C$6.5M2
Accumetrics 2/2008Series D$28.8M7
Oraya Therapeutics 1/2008Series B$18M2
Corium International 9/2007Series C$40M3
Oraya Therapeutics 6/2007Series A$4M1
StrataGent Life Sciences 5/2007Series B$16M2
Ception Therapeutics 1/2007Series C$63M5
NeoVista 12/2006Series C$41M6
Chroma Therapeutics 4/2006Series C$53M5
Symphogen 1/2006Series D$25M6
Light Sciences Oncology 12/2005Series A$67M8
Accumetrics 7/2004Series B$13.5M5



  1. QSpex Spots $15M Series E to Make Lenses for Glasses More Quickly ( [edit]
  2. Skincare company PreCision Dermatology receives $67 mln from Golub Capital ( [edit]
  3. Revance closes $33 million series E ( [edit]
  4. VC Funding: Q2 2013 source [edit]
  5. Kona Medical raises $10 million in new Series C funding ( [edit]
  6. SEC ( [edit]
  7. QSpex Technologies Secures approximately $20.5 Million in Series D Funding; Appoints New Director ( [edit]
  8. Kona Medical Raises $30M in Series C Financing ( [edit]
  9. VC Funding: Q2 2012 source [edit]
  10. IntegenX Garners $40,000,000 Series C Financing Round ( [edit]
  11. BreatheAmerica Closes $22M Series B Equity Financing ( [edit]
  12. Entellus Medical Completes $35M Funding Round ( [edit]
  13. Revance Therapeutics Closes $45M Financing ( [edit]
  14. Symphogen, AS: Series F $135.4M ( [edit]
  15. Symphogen Closes €100M Round of Financing ( [edit]
  16. Endologix to Acquire Nellix ( [edit]
  17. Cell Biosciences Nabs $20M ( [edit]
  18. Accumetrics Raises Additional $7M ( [edit]
  19. Complete Genomics, Inc. Announces Completion of $39 Million Series E Financing ( [edit]
  20. TearScience, Inc.: Series C $44.5M ( [edit]
  21. Accumetrics, Inc.: Series E $16.6M ( [edit]
  22. Essex Woodlands, Providence Equity Invest $120M In IkaSystems ( [edit]
  23. Swiss Protein Therapy Co. Molecular Partners Pulls In $44M Series B ( [edit]
  24. MorningStar ( [edit]
  25. SEC D/A ( [edit]
  26. Complete Genomics bags $45M round for sequencing ( [edit]
  27. Oraya garners $42M in third venture round ( [edit]
  28. Capital Report Index [edit]
  29. Symphogen secures € 33 million financing to support clinical development of antibody products ( [edit]
  30. Catalyst Biosciences Raises $40 Million in Series C Financing ( [edit]
  31. Nellix raises $6.5M for aneurysm grafts ( [edit]
  32. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial ( [edit]
  33. Secretive Oraya raises more funds for eye devices ( [edit]
  34. Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures ( [edit]
  35. Stealthy Oraya raises $4M for medical devices ( [edit]
  36. StrataGent closes $16M round for needle-free injections ( [edit]
  37. Ception Therapeutics Raises $63 Million in Series C Financing ( [edit]
  38. NeoVista, a co. targeting age-related macular degeneration, raises $41M ( [edit]
  40. Symphogen gets $25M for clinical trials for bleeding treatment ( [edit]
  41. Light Sciences Oncology Completes Second Closing in $67 Million Financing for Late Stage Development of Litx(TM) and Announces Additional Directors; Investors' Additional $32 Million Completes Offering of Series A Preferred ( [edit]
  42. SEC D/A ( [edit]
Edit This Page
Last Edited 4/11/14

Revision History RSS Picture


Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API


Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy